Back to results
US 2026/0216226 A1Published application
Triple combined therapy inhibiting egfr, raf1 and stat3 against pancreatic ductal adenocarcinoma
AssigneeFundacion Del Sector Publico Estatal Centro Nacional De Investigaciones Oncol
InventorsMariano BARBACID, Carmen GUERRA, Vasiliki LIAKI
Life of this patent
Estimating the term…
Abstract
The present invention relates to a pharmaceutical composition comprising an inhibitor of the expression, activity and/or function of c-Raf, an inhibitor of the expression, activity and/or function of EGF Receptor (EGFR), and an inhibitor of the expression, activity and/or function of STAT3 and its use in the treatment of pancreatic cancer.
Claims14
A pharmaceutical composition comprising:
- a. an inhibitor of the expression, activity and/or function of c-Raf;
- b. an inhibitor of the expression, activity and/or function of EGF Receptor (EGFR);
- c. an inhibitor of the expression, activity and/or function of STAT3.
Dependencies are inferred from the claim text.